Involved in SBIR from soon after the firm was established, Implant Sciences Corporation (Implant Sciences) publicly traded from mid-1999 until 2017. In the early days the firm earned a good reputation - developing leading technologies in several markets, including medical products and semiconductor manufacturing. A number of deals and collaboration organized around the firm's work in the radiation therapy implants and thin film device coating space. In 2008 the Company restructured to a single business focus - a pure play in global Security, Safety, and Defense (SS&D) markets. The Companys patented technology, used in its flagship products, the QS-H150 handheld explosives trace detector and the QS-B220 desktop explosives and drugs trace detector, is in use throughout the world.developing, manufacturing and selling sensors and systems for the security, safety and defense (SS&D) industries. Its technologies are used worldwide in security and inspection applications. Implant Sciences has developed technologies used in explosives trace detection (ETD), and and narcotics trace detection (NTD) applications and market and sell handheld ETD and benchtop ETD and NTD systems that use its technologies. The systems are used by private companies and Government agencies to screen baggage, cargo, vehicles, other objects and people for the detection of trace amounts of explosives. Implant Sciences have developed explosives detection systems designed for use in aviation and transportation security, high threat facilities and infrastructure, military installations, customs and border protection, and mail and cargo screening. In January 2017, it was announced that L3 Technologies - already having by far the the largest number of SBIR acquisitions - had completed acquisition of Implant Sciences' Explosives Trace Detection (ETD) assets.
